Zhou Peng, Li Xuemin
Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, P.R. China.
Oncol Lett. 2019 Jul;18(1):307-313. doi: 10.3892/ol.2019.10331. Epub 2019 May 7.
The aim of the present study was to investigate the expression of microRNA (miR)-338-5p in retinoblastoma(RB), thereby evaluating whether it could have potential as a biomarker to screen patients with RB from healthy controls. The results revealed that miR-338-5p was significantly upregulated in patients with RB compared with in healthy controls. There was no significant difference in the expression of miR-338-5p between patients with RB of different age, sex, tumor stage or binocular disease. Receiver operator characteristic analysis indicated that serum miR-338-5p combined with neuron-specific enolase (NSE) had a larger area under the curve compared with serum miR-338-5p alone when diagnosing RB. In addition, suppression of miR-338-5p induced slower proliferation of ACBRI-181 and Y79 cells at 2, 3, 4 and 5 days compared with the negative control group. Flow cytometric analysis indicated that transfection with miR-338-5p inhibitor leads to significant cell cycle arrest in ACBRI-181 and Y79 cells compared with in the negative control group. Furthermore, transfection with miR-338-5p inhibitor significantly decreased ACBRI-181 and Y79 cell migration and invasion, suggesting that miR-338-5p may serve an oncogenic role in the progression of RB. In conclusion, the low expression of miR-338-5p in the serum of patients with RB suggests that it may be involved in the formation of RB. Serum miR-338-5p has the potential to be a tumor marker of RB, and, in combination with NSE, miR-338-5p may improve the early diagnosis rate of RB.
本研究旨在探讨微小RNA（miR）-338-5p在视网膜母细胞瘤（RB）中的表达，从而评估其是否有潜力作为从健康对照中筛选RB患者的生物标志物。结果显示，与健康对照相比，RB患者中miR-338-5p显著上调。不同年龄、性别、肿瘤分期或双眼疾病的RB患者之间，miR-338-5p的表达无显著差异。受试者工作特征分析表明，在诊断RB时，血清miR-338-5p与神经元特异性烯醇化酶（NSE）联合使用时曲线下面积比单独使用血清miR-338-5p更大。此外，与阴性对照组相比，抑制miR-338-5p可在第2、3、4和5天诱导ACBRI-181和Y79细胞增殖减缓。流式细胞术分析表明，与阴性对照组相比，转染miR-338-5p抑制剂可导致ACBRI-181和Y79细胞出现明显的细胞周期停滞。此外，转染miR-338-5p抑制剂可显著降低ACBRI-181和Y79细胞的迁移和侵袭能力，提示miR-338-5p可能在RB进展中发挥致癌作用。总之，RB患者血清中miR-338-5p的低表达表明其可能参与了RB的形成。血清miR-338-5p有潜力成为RB的肿瘤标志物，并且与NSE联合使用时，miR-338-5p可能提高RB的早期诊断率。
